A Phase 1/2 interventional study of VIR-3434 and VIR-2218 in Hepatitis B, Chronic, sponsored by Vir Biotechnology, Inc.. Completed at 15 sites in 6 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Vir Biotechnology, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Hepatitis B, Chronic with a site in France — 8 open to participants now, 10 under way, none of them phase 3. Hepatitis B, Chronic · France.
Among the 54 studies in Hepatitis B, Chronic with a site in France, this one is the 40th largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 1/2, and was the 43rd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →8 of the 54 studies in Hepatitis B, Chronic with a site in France are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in France, United States, Canada and 3 more countries
Ages 18–65
nChroma Bio · Sites in France, Hong Kong, New Zealand and 1 more country
Ages 18–64
University Hospital, Limoges · Sites in France
Ages 18+ · Healthy volunteers
Precision BioSciences, Inc. · Sites in France, United States, Hong Kong and 3 more countries
Ages 18–70
Hospices Civils de Lyon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 66 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 14 · Phase 4 2
First in 2001; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 135 across the 44 interventional studies, 1,360 across the 9 observational. Of the 40 that completed or were terminated, 25 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 54 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
4 of the studies in Hepatitis B, Chronic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06680232Precision BioSciences, Inc.Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B | 2026-12 |
| NCT06963710Aligos TherapeuticsA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | 2027-03 |
| NCT07654283AusperBio Therapeutics Inc.Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions | 2027-05-11 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Hepatitis B, Chronic with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
VIR-SHB1-V201 (STRIVE) Sub-Protocol A is a Phase 2 study under the PREVAIL platform trial. This is a multi-center, open-label study designed to evaluate the safety and efficacy of regimens containing VIR-3434, VIR-2218, PEGASYS (PEG-IFNα), and nucleotide reverse transcriptase inhibitors (NRTI) in noncirrhotic adult participants with chronic HBV infection that have not received prior NRTI or PEGASYS treatment.
VIR-SHB1-V202 (THRIVE) Sub-Protocol B is a Phase 2 study under the PREVAIL platform trial. This is a multi-center open-label study designed to evaluate the safety and efficacy of regimens containing VIR-3434 and NRTI with or without VIR-2218 in noncirrhotic adult participants with low viral burden of chronic HBV infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
Drug: VIR-3434 · Drug: TDF
Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total
Drug: VIR-3434 · Drug: TDF
Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total
Drug: VIR-3434 · Drug: TDF
Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total
Drug: VIR-3434 · Drug: VIR-2218 · Drug: TDF
Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total
Drug: VIR-3434 · Drug: VIR-2218 · Drug: TDF · Drug: PEG-IFNα
Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks
Drug: VIR-3434 · Drug: TDF
Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total
Drug: VIR-3434 · Drug: VIR-2218 · Drug: TDF
STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment
Time frame: Up to 48 weeks
STRIVE and THRIVE: Proportion of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Up to 96 weeks
STRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at End of Treatment
Time frame: Up to 48 weeks
STRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at 24 Weeks Post-end of Treatment
Time frame: Up to 72 weeks
STRIVE and THRIVE: Serum HBsAg Levels and Change From Baseline Across Timepoints in the Study
Time frame: Up to 96 weeks
STRIVE and THRIVE: Serum HBsAg Level at Nadir During the Study
Time frame: Up to 96 weeks
STRIVE and THRIVE: Time to Achieve Nadir of Serum HBsAg During the Study
Time frame: Up to 96 weeks
STRIVE and THRIVE: Time to Achieve Serum HBsAg Loss (< 0.05 IU/mL)
Time frame: Up to 96 weeks
STRIVE and THRIVE: Proportion of Participants With HBsAg Loss With Anti-HBs Seroconversion at End of Treatment and at 24 Weeks Post-end of Treatment
Time frame: Up to 76 weeks
STRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit
Time frame: Up to 96 weeks
STRIVE: Proportion of Participants With HBsAg Loss (<0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment
Time frame: Up to 72 weeks
STRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit
Time frame: Up to 96 weeks
STRIVE: For HBeAg-positive Participants: Proportion of Participants With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion
Time frame: Up to 72 weeks
STRIVE: Incidence and Titers of Anti-drug Antibodies (ADA; if Applicable) to VIR-3434
Time frame: Up to 96 weeks
STRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study
Time frame: Up to 96 weeks
STRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ) Across Timepoints in the Study
Time frame: Up to 96 weeks
STRIVE: Proportion of Participants Achieving ALT ≤ ULN Across Timepoints in the Study
Time frame: Up to 96 weeks
THRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks
Time frame: Up to 92 weeks
THRIVE: Proportion of Participants Achieving HBsAg Loss (< 0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment
Time frame: Up to 44 weeks
THRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks
Time frame: Up to 68 weeks
THRIVE: Incidence and Titers of ADA (if Applicable) to VIR-3434
Time frame: Up to 92 weeks
THRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study
Time frame: Up to 92 weeks
THRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ)
Time frame: Up to 92 weeks
| Milestone | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 16 | 0 | 0 | 17 |
| Completed | 0 | 0 | 0 | 11 | 0 | 0 | 17 |
| Not completed | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
| Participants | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) |
|---|---|---|---|---|---|---|---|
| STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment | — | — | — | 1 | — | — | 4 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over 48 Weeks. Non-serious events are listed at a 1.25% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| STRIVE: Cohort 1a (VIR-3434 + TDF) | — | — | — |
| STRIVE: Cohort 2a (VIR-3434 + TDF) | — | — | — |
| STRIVE: Cohort 3a (VIR-3434 + TDF) | — | — | — |
| STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | — | 0/16 (0%) | 11/16 (68.8%) |
| STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | 0/16 (0%) | — | — |
| THRIVE: Cohort 1b (VIR-3434 + TDF) | — | — | — |
| THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | 0/17 (0%) | 1/17 (5.9%) | 12/17 (70.6%) |
| Event | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | — | — | — | 0/16 | — | — | 1/17 |
| Event | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | — | — | — | 5/16 | — | — | 2/17 |
| Influenza like illnessGeneral disorders | — | — | — | 0/16 | — | — | 4/17 |
| Alpha 1 foetoprotein increasedInvestigations | — | — | — | 3/16 | — | — | 0/17 |
| ChillsGeneral disorders | — | — | — | 2/16 | — | — | 2/17 |
| FatigueGeneral disorders | — | — | — | 2/16 | — | — | 2/17 |
| Injection site erythemaGeneral disorders | — | — | — | 2/16 | — | — | 1/17 |
| Injection site painGeneral disorders | — | — | — | 2/16 | — | — | 0/17 |
| MyalgiaMusculoskeletal and connective tissue disorders | — | — | — | 2/16 | — | — | 2/17 |
| Upper respiratory tract infectionInfections and infestations | — | — | — | 2/16 | — | — | 1/17 |
| NauseaGastrointestinal disorders | — | — | — | 2/16 | — | — | 1/17 |
cohort 1a, 2a,3a, 5a and 1b were not open for enrollment
| Age, Categorical(Participants) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 16 | 0 | 0 | 17 | 33 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| STRIVE: Cohort 4a | — | — | — | 43.3 ± 9.67 | — | — | 0 ± 0 | 43.3 ± 9.67 |
| THRIVE: Cohort 2b | — | — | — | 0 ± 0 | — | — | 48.4 ± 9.78 | 48.4 ± 9.78 |
| Sex: Female, Male(Participants) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | — | — | — | 10 | — | — | 9 | 19 |
| Male | — | — | — | 6 | — | — | 8 | 14 |
| Ethnicity (NIH/OMB)(Participants) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | — | — | — | 0 | — | — | 0 | 0 |
| Not Hispanic or Latino | — | — | — | 16 | — | — | 17 | 33 |
| Unknown or Not Reported | — | — | — | 0 | — | — | 0 | 0 |
| Race (NIH/OMB)(Participants) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | — | — | — | 0 | — | — | 0 | 0 |
| Asian | — | — | — | 6 | — | — | 7 | 13 |
| Native Hawaiian or Other Pacific Islander | — | — | — | 0 | — | — | 0 | 0 |
| Black or African American | — | — | — | 2 | — | — | 5 | 7 |
| White | — | — | — | 7 | — | — | 5 | 12 |
| More than one race | — | — | — | 0 | — | — | 0 | 0 |
| Unknown or Not Reported | — | — | — | 1 | — | — | 0 | 1 |
| Region of Enrollment(Participants) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| New Zealand | — | — | — | 0 | — | — | 0 | 0 |
| South Korea | — | — | — | 1 | — | — | 5 | 6 |
| Romania | — | — | — | 6 | — | — | 2 | 8 |
| Hong Kong | — | — | — | 4 | — | — | 2 | 6 |
| United Kingdom | — | — | — | 3 | — | — | 3 | 6 |
| Moldova | — | — | — | 0 | — | — | 2 | 2 |
| France | — | — | — | 2 | — | — | 3 | 5 |
| Thailand | — | — | — | 0 | — | — | 0 | 0 |
| Hepatitis B surface antigen (Log10 IU/mL)(Log10 IU/mL) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| STRIVE: Cohort 4a | — | — | — | 3.64 ± 0.72 | — | — | 0 ± 0 | 3.64 ± 0.72 |
| THRIVE: Cohort 2b | — | — | — | 0 ± 0 | — | — | 3.12 ± 0.66 | 3.12 ± 0.66 |
| Hepatitis B e antigen status(Participants) | STRIVE: Cohort 1a (VIR-3434 + TDF) | STRIVE: Cohort 2a (VIR-3434 + TDF) | STRIVE: Cohort 3a (VIR-3434 + TDF) | STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF) | STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα) | THRIVE: Cohort 1b (VIR-3434 + TDF) | THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF) | Total |
|---|---|---|---|---|---|---|---|---|
| HBeAg positive | — | — | — | 3 | — | — | 0 | 3 |
| HBeAg negative | — | — | — | 13 | — | — | 17 | 30 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Oct 2024, 17 months.
Results were first posted in Nov 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tobevibart